Exelixis Inc Payments for Restructuring
Exelixis Inc (EXEL) reported Payments for Restructuring of $17.73 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-10
- Exelixis Inc payments for restructuring for the quarter ending 2026-01-02 was $14.67M.
- Exelixis Inc payments for restructuring for the quarter ending 2016-12-31 was $362.00K.
- Exelixis Inc payments for restructuring for the quarter ending 2016-09-30 was $2.17M.
- Exelixis Inc payments for restructuring for the quarter ending 2016-06-30 was $890.00K.
- Exelixis Inc payments for restructuring for fiscal 2026 was $17.73M.
- Exelixis Inc payments for restructuring for fiscal 2016 was $4.57M, a 48.19% decline from fiscal 2015.
- Exelixis Inc payments for restructuring for fiscal 2015 was $8.83M, a 13.77% decline from fiscal 2014.
- Exelixis Inc payments for restructuring for fiscal 2014 was $10.24M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed | Payments for Restructuring 42 month | Payments for Restructuring 45 month | Payments for Restructuring 46 month | Payments for Restructuring 49 month | Payments for Restructuring 52 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | $14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $17.73M 10-K · filed 2026-02-10 | ||||||||
| 2025-10-03 | $3.05M 10-Q · filed 2025-11-04 | |||||||||
| 2016-12-31 | $362.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $2.53M derived: sum of 2 quarters · filed 2017-02-27 | $3.42M derived: sum of 3 quarters · filed 2017-02-27 | $4.57M 10-K · filed 2017-02-27 | ||||||
| 2016-09-30 | $2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $3.06M derived: sum of 2 quarters · filed 2016-11-03 | $4.21M 10-Q · filed 2016-11-03 | |||||||
| 2016-06-30 | $890.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $2.04M 10-Q · filed 2016-08-03 | ||||||||
| 2016-03-31 | $1.15M 10-Q · filed 2016-05-04 | |||||||||
| 2015-12-31 | $8.83M 10-K · filed 2017-02-27 | |||||||||
| 2014-12-31 | $10.24M 10-K · filed 2017-02-27 | |||||||||
| 2014-06-30 | $2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $3.50M 10-Q · filed 2014-07-31 | $4.24M derived: sum of 3 quarters · filed 2014-07-31 | $6.33M derived: sum of 4 quarters · filed 2014-07-31 | $38.70M 10-Q · filed 2014-07-31 | |||||
| 2014-03-31 | $1.41M 10-Q · filed 2014-05-01 | $2.14M derived: sum of 2 quarters · filed 2014-07-31 | $4.24M derived: sum of 3 quarters · filed 2014-07-31 | $36.60M 10-Q · filed 2014-05-01 | ||||||
| 2013-12-31 | $733.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-07-31 | $2.83M derived: sum of 2 quarters · filed 2014-07-31 | $6.76M 10-Q · filed 2014-07-31 | $35.40M 10-K · filed 2014-02-20 | ||||||
| 2013-09-30 | $2.10M derived: 10-Q 45 month − 10-Q 42 month · filed 2013-10-30 | $6.03M 10-Q · filed 2013-10-30 | $34.80M 10-Q · filed 2013-10-30 | |||||||
| 2013-06-30 | $32.70M 10-Q · filed 2013-08-06 | |||||||||
| 2012-12-31 | $6.27M 10-K · filed 2014-02-20 | |||||||||
| 2011-12-31 | $10.85M 10-K · filed 2014-02-20 | $9.30M 10-K · filed 2012-02-22 | ||||||||
| 2010-12-31 | $14.28M 10-K · filed 2014-02-20 | $14.10M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |